Dr. David Fivenson joins the Vial network

fivenson
fivenson

We are thrilled to welcome Dr. David Fivenson as the newest investigator in the Vial network. Fivenson Dermatology’s clinical research team bring over 30 years of clinical research experience and spans leading indications in Dermatology. With the addition of Fivenson Dermatology, in Ann Arbor, MI, Vial has partnered with highly respected, extensively published and widely respected Dermatologists.

Dr. David Fivenson has supported and operated trials in Atopic Dermatitis, Vitiligo, Hidradenitis Suppurativa, Rosacea, Chronic Spontaneous Urticaria, Pruritus (itch), Prurigo Nodularis, Basal Cell Carcinoma, Psoriasis, Acne, Bullous Pemphigoid, Pemphigus, Onychomycosis, Warts, and several others. The research team has support trials run by large and small sponsors including DermTech, Lilly, BMS, Leo Pharma, Principia Biopharma, Abbvie, Regeneron, Amgen, Trevi, BMS, Biogen and many others.

“I’m excited to work with the Vial team. They have impressed me with their thoughtfulness on the challenges that face PIs like me and have built a product around our needs. The Vial model is additive and brings me value in more trials for my clinic and more streamlined management of regulatory paperwork. From patient recruiting efforts across our trials and to hiring support staff and managing an unforeseen issues – they focus on delivering for our needs.” said Dr. David Fivenson.

The partnership is overseen by Vial’s Head of Dermatology Justin Withers, “Dr. Fivenson is a truly phenomenal investigator who is deeply respect by his Dermatologist peers, academics and sponsors. We are honored to partner with him to grow the Fivenson Dermatology clinical operations team. Our focus now is on increasing recruitment on trials and maintaining their reputation for meticulous data management.”

Background

Dr. Fivenson is a native Michigander, growing up in Alpena. He attended The University of Michigan for undergraduate and medical schools. He did his Dermatology Residency at the University of Cincinnati and Immunodermatology Fellowship at the University of California, San Diego. He is board certified in dermatology and immunodermatology, From 1989-2002 he was in full-time academic practice at Henry Ford Hospital, prior to starting this practice. He is a nationally recognized specialist in autoimmune skin disease, wound care, clinical research and cutaneous T cell lymphoma, He has published over 140 peer-reviewed articles has lectured extensively at national and international medical conferences and has been repeatedly listed with Who’s Who in America, Best Doctors in America and Castle Connelly’s Top Docs. Dr. Fivenson is on the editorial board of the Journal of the American Academy of Dermatology as well as a peer reviewer for several other dermatology journals. He has been an investigator on more than 150 clinical trials for both common and rare skin diseases.

Dr. Fivenson is part of the St. Joseph Mercy Health System Dermatology Residency Program and is Program Director for the Complex Medical Dermatology Fellowship which is supported by St. Joseph Mercy Health System Dermatology Graduate Medical Education.

About Vial:
Vial’s mission is to run clinical trials with faster execution and higher quality in order to bring
new therapies to market. Vial has over 70 employees and is based in San Francisco, California.
Vial partners with Dermatologists to support their research teams and has created a network of
over 35 Dermatology clinics. The Vial network has contributed to over 150 trials for many of the
leading Sponsors in Dermatology having run trials across common Medical Dermatology
indications (Atopic Dermatitis, Psoriasis, Vitiligo, Alopecia Areata, Rosacea, Hidradenitis
Suppurativa, Prurigo Nodularis among others) as well as Cosmetic Dermatology indications. The
clinic network runs trials from Phase I through Phase IV.